Original Article
Copyright ©2014 Baishideng Publishing Group Inc.
World J Transplant. Sep 24, 2014; 4(3): 188-195
Published online Sep 24, 2014. doi: 10.5500/wjt.v4.i3.188
Table 1 Demographic features
r-ATG
Alemtuzumab
IL-2 receptor blocker
SteroidNo steroidSteroidNo steroidSteroidNo steroid
(n = 13001)(n = 4862)(n = 852)(n = 2176)(n = 15008)(n = 1318)
Donor age (yr)39 ± 1739 ± 1741 ± 1840 ± 1737 ± 1737 ± 17
Donor gender (M/F) (%)59/4160/4061/3958/4260/4060/40
Donor death from CVA (%)4340b41434036b
ECD kidney (%)19192622b1516
DCD kidney (%)9.88.914.110.9a5.36.7a
Recipient age (yr)52 ± 1353 ± 13d52 ± 1353 ± 1252 ± 1354 ± 15d
Recipient gender (M/F) (%)57/5363/37d56/4460/40a63/3764/36
African American race (%)3726d33332620d
Diabetes (%)3420d3138b3434
Pre-txp dialysis (%)9188b88889187d
Dialysis duration (mo)48 ± 3543 ± 36d47 ± 3750 ± 3443 ± 3341 ± 32
Peak PRA (%)18 ± 3110 ± 22d19 ± 3114 ± 27d9 ± 228 ± 20
HLA mismatches3.9 ± 1.83.8 ± 1.8a3.9 ± 1.83.7 ± 1.7b3.6 ± 1.93.5 ± 2.0
Cold ischemia (h)18.3 ± 8.218.5 ± 8.820.8 ± 8.720.5 ± 9.217.8 ± 7.917.4 ± 8.5
Delayed graft function (%)28.919.5d29.121.2d20.216.5
Discharged on tacrolimus (%)8179b7098d6778d